实体器官移植后浆细胞骨髓瘤的临床与病理特征
该研究回顾性分析了本机构诊断和治疗的15例移植后浆细胞骨髓瘤(PT-PCM)及2例移植后意义未明单克隆丙种球蛋白病(PT-MGUS)病例,发现PT-PCM占所有单形性移植后淋巴增殖性疾病(M-PTLD)的11.6%,中位移植后发病时间为9.7年,免疫表型及细胞遗传学异常与免疫功能正常个体的多发性骨髓瘤(MM)相似,治疗反应及5年总生存率(54.5%)与免疫功能正常个体MM相当,但浆母细胞型患者生存劣于未成熟型。
要点
- PT-PCM占所有M-PTLD的11.6%,肾脏、心脏、肝脏和肺移植后期间患病率分别为0.29%、0.28%、0.15%和0.11%。
- PT-PCM中位移植后发病时间为9.7年(范围0.5-24.7年),中位年龄68岁(范围29-79岁),男女比例4:1。
- 所有PT-PCM均为EBER阴性,60%病例存在细胞遗传学异常,免疫表型与免疫功能正常个体MM相似。
核心结论
- PT-PCM主要为晚发性PTLD,其临床病理特征与常规MM相似,治疗反应和5年总生存率(54.5%)与免疫功能正常个体MM相当,但浆母细胞型患者生存劣于未成熟型。
研究设计与样本
- 本研究为单中心回顾性研究,纳入本机构诊断和治疗的15例PT-PCM(男女比例4:1)和2例PT-MGUS(均为男性)病例,进行综合免疫表型分析、细胞遗传学结果回顾及临床结局评估。
主要发现
- PT-PCM占所有M-PTLD的11.6%;肾脏、心脏、肝脏和肺移植后期间患病率分别为9/3108(0.29%)、3/1071(0.28%)、2/1345(0.15%)和1/878(0.11%)。
- PT-PCM患者中位年龄68岁(范围29-79岁),移植后中位发病时间9.7年(范围0.5-24.7年)。
- 溶骨性骨病见于1/11(9%)患者;骨髓浆细胞浸润范围10%-70%(中位20%),10/15(67%)为未成熟形态,5/15(33%)为浆母细胞形态。
- 所有病例免疫表型与免疫功能正常个体MM相似;60%病例检出细胞遗传学异常;所有PT-PCM均为EBER阴性。
- 11例活动性MM患者中10例(91%)接受治疗,均含蛋白酶体抑制剂方案;治疗反应和5年总生存率(54.5%)与免疫功能正常个体MM相当;浆母细胞型PCM患者生存劣于未成熟型PCM患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Plasma cell neoplasms (PCNs), comprising plasma cell myelomas (PCMs) and plasmacytomas, which occur after solid organ transplantation, represent rare subtypes of monomorphic post-transplant lymphoproliferative disorders (M-PTLDs). Data regarding the clinical and pathological features of post-transplant (PT)-PCMs are limited. To gain a better understanding of disease biology, we performed comprehensive immunophenotypic analysis, reviewed cytogenetic analysis results and evaluated clinical outcomes of PT-PCMs diagnosed and treated at our institution. Fifteen PT-PCM (M: F - 4:1) and two PT-MGUS (two males) cases were identified. The median age of PT-PCM patients was 68 years (29-79 years) and PCMs presented at a median of 9.7 years (0.5-24.7 years) after transplantation. The PT-PCMs accounted for 11.6% of all M-PTLDs and the period prevalence was 9/3108 (0.29%), 3/1071 (0.28%), 2/1345 (0.15%) and 1/878 (0.11%) post kidney, heart, liver and lung transplantation. Lytic bone disease was observed in 1/11 (9%) patients. Marrow plasma cell infiltration ranged from 10%-70% (median 20%), with 10/15 (67%) and 5/15 (33%) cases manifesting immature and plasmablastic morphology. The immunophenotype of all cases and cytogenetic abnormalities, identified in 60% of cases, were similar to multiple myeloma (MM) of immunocompetent individuals. All PT-PCMs were EBER negative. Ten of 11 (91%) patients with active MM were treated, all with proteasome inhibitor-based therapy. Treatment response and 5-year overall survival (54.5%) was comparable to MM of immunocompetent individuals. However, the survival of patients with plasmablastic PCMs was inferior to those with immature PCMs. 0ur findings indicate PT-PCMs to be predominantly late onset PTLDs that have similar clinicopathologic characteristics as conventional MM.
引用
- Ofori K, Soderquist CR, Murty VV, et al. The clinical and pathological features of plasma cell myeloma post solid organ transplantation. Am J Hematol. 2020. PMID: 32864761. doi:10.1002/ajh.25988
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。